Will this trial change my practice? ACCOAST - early loading with a novel P2Y12 inhibitor in patients with an acute coronary syndrome

MeSH terms

• Acute Coronary Syndrome / blood
• Acute Coronary Syndrome / diagnosis
• Acute Coronary Syndrome / drug therapy*
• Drug Administration Schedule
• Evidence-Based Medicine
• Hemorrhage / chemically induced
• Humans
• Multicenter Studies as Topic
• Percutaneous Coronary Intervention
• Piperazines / administration & dosage*
• Piperazines / adverse effects
• Platelet Aggregation Inhibitors / administration & dosage*
• Platelet Aggregation Inhibitors / adverse effects
• Practice Patterns, Physicians'
• Prasugrel Hydrochloride
• Purinergic P2Y Receptor Antagonists / administration & dosage*
• Purinergic P2Y Receptor Antagonists / adverse effects
• Randomized Controlled Trials as Topic
• Receptors, Purinergic P2Y12 / blood
• Receptors, Purinergic P2Y12 / drug effects*
• Risk Factors
• Thiophenes / administration & dosage*
• Thiophenes / adverse effects
• Time Factors
• Treatment Outcome